Patterns of Local-Regional Failure in Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer Cases: Implications for Postoperative Radiation Therapy Clinical Target Volume Design

Feng, Wen; Fu, Xiaolong; Cai, Xu; Yang, Huan; Wu, Keyi; Fan, Min; Xiang, Jia; Zhang, Ya Wei; Chen, Hai Quan

doi:10.1016/j.ijrobp.2013.12.048

Cited by 42 publications

(57 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung adenocarcinoma is the most common pathological type of lung cancer . Rapid progression, easy to metastasize and chemoresistance are the challenges faced by treatment . The discovery and application of new molecular targets that reflect tumor biological behavior, and even potentially be a therapeutic target, may be helpful.…”

Section: Discussionmentioning

confidence: 99%

Effect of IDH3a on glucose uptake in lung adenocarcinoma: A pilot study based on [¹⁸F]FDG

Diao

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

Subunit of isocitrate dehydrogenase 3 (IDH3a) as upstream of the hypoxia‐inducible factor was reported highly expressed in malignant tumors, playing an important role in glucose metabolism reprogramming. As one of rate‐limiting enzyme in the Krebs cycle, whether high expression of IDH3a affects glucose uptake in tumors has not been elucidated. This study was aimed to investigate the relationship between IDH3a expression and tumor glucose uptake. Sixty‐five patients who underwent 2‐[ 18 F]‐2‐deoxy‐D‐glucose ([ 18 F]‐FDG) positron emission tomography/computed tomography (PET/CT) imaging before surgery and pathologically diagnosed as lung adenocarcinoma were included. All patients were divided into high (n = 31) and low (n = 34) groups according IDH3a expression by immunohistochemistry. Comparatively higher [ 18 F]‐FDG uptake was found in high IDH3a expression group. Glucose transporter 1 (GLUT1) level was demonstrated to correlate with IDH3a expression, but not for hexokinase 2 (HK2). Furthermore, A549 and H1299 cells experiment showed, the expression of p‐AKT and GLUT1 were significantly downregulated after IDH3a interference. The cellular uptake of [ 18 F]‐FDG and lactate production were significantly reduced in treatment group. In summary, high expression of IDH3a in lung adenocarcinoma patients is associated with higher glucose uptake. IDH3a targets AKT‐GLUT1 pathway to affect glucose uptake and metabolites in lung adenocarcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of IDH3a on glucose uptake in lung adenocarcinoma: A pilot study based on [¹⁸F]FDG

Diao

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…In 2014, Feng et al 13 published recurrence data for patients with N2 disease treated with surgery alone, without postoperative radiation. Of 250 patients, 173 relapsed, and the sites of first relapse were locoregional only in 29, locoregional and distant in 25, and distant in 119.…”

Section: Main Findingsmentioning

confidence: 99%

Causes of Death and Subsequent Treatment after Initial Radical or Palliative Therapy of Stage iii Non-Small-Cell Lung Cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…[2][3][4][5][6] Nonetheless, even after complete resection and postoperative chemotherapy, the rate of locoregional failure can be up to 30% to 40%. 7 Postoperative radiotherapy (PORT) to the mediastinum for microscopic disease is reported to reduce local recurrence in patients with pN2 squamous cell lung cancer. 8 In a meta-analysis of nine trials involving >2000 patients, PORT for completely resected NSCLC was reported to result in a 7% increase in overall mortality at 2 years, and non-significant survival benefit in the pN2 subgroup.…”

Section: Introductionmentioning

confidence: 99%

Postoperative Radiotherapy for Resected Stage IIIA–N2 Non-small-cell Lung Cancer: a Review of Outcomes

Lam¹,

Lim²,

Tong³

et al. 2018

Hong Kong J Radiol

View full text Add to dashboard Cite

Objective:To review the outcomes of postoperative radiotherapy (PORT) using three-dimensional conformal techniques in patients with resected pathological N2 (pN2) non-small-cell lung cancer (NSCLC). Methods: Consecutive patients who underwent PORT for resected pN2 NSCLC were retrospectively reviewed. Adjuvant chemotherapy was given before PORT. Locoregional and systemic recurrences, disease-free survival (DFS), and overall survival (OS) were estimated using the Kaplan-Meier method. Factors associated with DFS and OS were determined using the log-rank test. Results: Eight men and seven women aged 38 to 76 (median, 65) years were included. All had stage IIIA cancer and underwent lobectomy. 12 and three patients had single and multiple mediastinal lymph node station involvement, respectively. The median numbers of resected lymph nodes and lymph node stations were 6 and 4, respectively. Only five patients underwent systematic nodal dissection or sampling. 13 patients underwent adjuvant chemotherapy. The median follow-up period was 31.9 months. Actuarial locoregional control was 100% at 1 year, 92.4% at 2 years, and 82.0% at 3 years. Ten patients had recurrence; all had distant metastases as the first failure event. The median time to recurrence was 12.6 months. DFS was 66.5% at 1 year, 46.5% at 2 years, and 40.0% at 3 years; the median DFS was 14.9 months. OS was 93.5% at 1 year, 66.5% at 2 years, and 51.5% at 3 years; the median OS was 42.4 months. There were nine deaths; eight were cancer-related and one was of unknown cause. Multiple pN2 lymph node station involvement was the only variable that was significant for both DFS and OS. Compared with patients with single pN2 lymph node station involvement, patients with multiple pN2 lymph node station involvement had shorter median DFS (10.9 months vs. 29.2 months, p = 0.008) and median OS (12.1 months vs. 54.1 months, p = 0.003). No patient had grade 3 or above toxicities. Conclusion: PORT using modern techniques and dose fractionation for patients with resected pN2 NSCLC was well tolerated and resulted in a high locoregional control rate, but the rate of distant metastasis remained high. Patients with multiple pN2 lymph node station involvement had worse survival.

show abstract

Patterns of Local-Regional Failure in Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer Cases: Implications for Postoperative Radiation Therapy Clinical Target Volume Design

Cited by 42 publications

References 28 publications

Effect of IDH3a on glucose uptake in lung adenocarcinoma: A pilot study based on [¹⁸F]FDG

Effect of IDH3a on glucose uptake in lung adenocarcinoma: A pilot study based on [¹⁸F]FDG

Causes of Death and Subsequent Treatment after Initial Radical or Palliative Therapy of Stage iii Non-Small-Cell Lung Cancer

Postoperative Radiotherapy for Resected Stage IIIA–N2 Non-small-cell Lung Cancer: a Review of Outcomes

Contact Info

Product

Resources

About

Patterns of Local-Regional Failure in Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer Cases: Implications for Postoperative Radiation Therapy Clinical Target Volume Design

Cited by 42 publications

References 28 publications

Effect of IDH3a on glucose uptake in lung adenocarcinoma: A pilot study based on [18F]FDG

Effect of IDH3a on glucose uptake in lung adenocarcinoma: A pilot study based on [18F]FDG

Causes of Death and Subsequent Treatment after Initial Radical or Palliative Therapy of Stage iii Non-Small-Cell Lung Cancer

Postoperative Radiotherapy for Resected Stage IIIA–N2 Non-small-cell Lung Cancer: a Review of Outcomes

Contact Info

Product

Resources

About

Effect of IDH3a on glucose uptake in lung adenocarcinoma: A pilot study based on [¹⁸F]FDG

Effect of IDH3a on glucose uptake in lung adenocarcinoma: A pilot study based on [¹⁸F]FDG